# A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database

> **NCT05236257** · — · COMPLETED · sponsor: **Bayer** · enrollment: 93 (actual)

## Conditions studied

- Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
- Infantile Fibrosarcoma

## Interventions

- **DRUG:** Larotrectinib (Vitrakvi, BAY2757556)
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT05236257
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-09-13
- **Final completion:** 2022-09-13
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2024-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05236257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05236257, "A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05236257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*